Welcome to our dedicated page for Inovio Pharmaceu SEC filings (Ticker: INO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inovio Pharmaceuticals filings document the regulatory record for a Nasdaq-listed biotechnology company developing DNA medicines for HPV-related diseases, cancer and infectious diseases. Form 8-K disclosures cover financial results, business updates, material agreements, at-the-market offering activity, warrant amendments and changes affecting security-holder rights.
Proxy materials describe shareholder voting matters, board governance, executive compensation and equity-award disclosures. The filing record also identifies the company’s registered common stock and capital-structure instruments, including common stock, Series A warrants and pre-funded warrants tied to public financing activity.
INOVIO PHARMACEUTICALS director Wendy L. Yarno received new equity awards as part of her non-employee director compensation. On May 20, 2026, she was granted 34,200 restricted stock units and options on 41,800 shares of common stock with a $1.23 exercise price.
The awards were granted under the 2023 Omnibus Incentive Plan. Both the restricted stock units and the stock options vest 100% on May 20, 2027, meaning they become fully earned on that date if service conditions are satisfied.
INOVIO PHARMACEUTICALS, INC. director Jay Shepard received equity awards as part of his non-employee director compensation. He was granted 34,200 restricted stock units, each representing a contingent right to one share of common stock, and 41,800 stock options with a $1.23 exercise price. Both the RSUs and the options were granted under the 2023 Omnibus Incentive Plan and are scheduled to vest 100% on May 20, 2027. These are compensation-related grants, not open-market purchases or sales.
INOVIO PHARMACEUTICALS, INC. director Ann Calby Miller received new equity awards as part of non-employee director compensation. She was granted 34,200 restricted stock units, each representing one future share of common stock, and 41,800 stock options with a $1.23 exercise price.
Both the RSUs and the options vest 100% on May 20, 2027 under the company’s 2023 Omnibus Incentive Plan. The options expire on May 20, 2036. These are compensation-related grants, not open‑market purchases or sales.
INOVIO PHARMACEUTICALS, INC. reported a routine equity compensation grant to director David B. Weiner. He was awarded 34,200 restricted stock units, each representing one share of common stock, and 41,800 common stock options with an exercise price of $1.23 per share. Both the RSUs and the options vest 100% on May 20, 2027, and the options expire on May 20, 2036. These awards were granted under the company’s 2023 Omnibus Incentive Plan pursuant to its non-employee director compensation policy and do not involve any open-market buying or selling of shares.
INOVIO PHARMACEUTICALS, INC. director Lota S. Zoth received new equity awards as part of non-employee director compensation. She was granted 34,200 restricted stock units, each representing one future share of common stock, and 41,800 stock options with a $1.23 exercise price.
Both the RSUs and options were granted under the company’s 2023 Omnibus Incentive Plan and are scheduled to vest 100% on May 20, 2027. These are compensation-related grants rather than open-market share purchases or sales.
INOVIO PHARMACEUTICALS, INC. director Roger D. Dansey received new equity compensation. On May 20, 2026, he was granted 34,200 restricted stock units and 41,800 stock options with a $1.23 exercise price. Both the RSUs and options vest 100% on May 20, 2027 under the 2023 Omnibus Incentive Plan.
INOVIO PHARMACEUTICALS director Simon X. Benito received new equity awards as part of his non-employee director compensation. On May 20, 2026, he was granted 34,200 restricted stock units, each representing one future share of common stock, and 41,800 stock options with a $1.23 exercise price.
Both the RSUs and options were granted under the 2023 Omnibus Incentive Plan and are scheduled to vest 100% on May 20, 2027, subject to applicable plan terms. These are compensation-related awards, not open-market share purchases or sales.
INOVIO PHARMACEUTICALS Chief Scientific Officer Laurent Humeau reported routine equity-compensation activity. On May 20, 2026, 6,027 restricted stock units vested, and 2,163 common shares were withheld at $1.23 per share to cover tax obligations, leaving him with 48,986 common shares held directly. He also received new awards of 27,440 restricted stock units and 34,160 stock options with a $1.73 exercise price, scheduled to vest in equal annual installments from February 26, 2027 through February 26, 2029.
INOVIO PHARMACEUTICALS, INC. Chief Medical Officer Michael John Sumner reported several equity compensation transactions on May 20, 2026. He exercised 9,450 restricted stock units, receiving common shares, and 2,693 shares were withheld by the company to cover related tax obligations.
Sumner also received a new grant of 37,684 restricted stock units, which vest in three annual installments from February 26, 2027 through February 26, 2029. In addition, he was granted 46,876 stock options with a $1.73 exercise price, vesting over the same three-year period under INOVIO’s amended 2023 Omnibus Incentive Plan, which shareholders approved on May 20, 2026.
INOVIO PHARMACEUTICALS, INC. CFO Peter Kies reported several equity compensation events on common stock and related awards. On May 20, 2026, 8,700 restricted stock units vested and were settled into common shares, with 4,688 shares withheld at a price of $1.23 to cover tax obligations. Following these transactions, he held 47,542 common shares directly and 375 common shares indirectly through his spouse. Kies also received new grants of 32,480 restricted stock units and 39,760 stock options with a $1.73 exercise price expiring on May 20, 2036, approved under Inovio’s amended and restated 2023 Omnibus Incentive Plan after shareholder approval.